No Data
Promising Phase 2 Results and Safety Profile Justify Buy Rating for BriaCell Therapeutics
Why DBV Technologies Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket
Reported Earlier, BriaCell Therapeutics Prices $5.5M Public Offering Of 7.4M Shares At $0.75/Share For Working Capital Requirements
BriaCell Therapeutics: Total Gross Proceeds From Offering Expected to Be Approximately $5.55M >BCT.T
BriaCell Therapeutics: Offering Is Expected to Close on Dec. 13 >BCT.T
BriaCell Therapeutics Intends To Offer To Sell Common Shares And Warrants In Public Offering; No Terms Disclosed
No Data
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
LeadByAnimals : Same thoughts here
LeadByAnimals : Swing play hopefully